SMR3A

Across TCGA pan-cancer cohorts, SMR3A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMR3A data layer compared with 11 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher SMR3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMR3A expression acts as an unfavorable survival marker.

COAD, LIHC, and LUAD are the cancer types where SMR3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.168	0.806	.002	24	view →
LIHC	OS	Median	All	0.119	0.704	.007	15	view →
LUAD	OS	Median	III,IV	0.142	0.690	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SMR3A–COAD (OS)

Open the COAD breakdown →